

**AMENDMENTS TO THE CLAIMS**

1-153. (canceled)

154. (previously presented): A method of autologous cell therapy comprising:

- (a) collecting a tissue or body fluid sample comprising mononuclear cells from a mammal;
- (b) expanding the cells to at least about  $10^8$  cells/milliliter, in the absence of exogenous interleukin-2, wherein the cells are expanded by contacting the cells with two or more mitogenic antibodies;
- (c) stimulating the cells *ex vivo* in the presence of IFN- $\gamma$ , anti-IL-4 antibody or IL-12 to alter their cytokine production profile to induce the differentiation of the cells into activated Th1 cells; and
- (d) reinfusing the activated Th1 cells into a subject in need of such an infusion.

155. (previously presented): The method of claim 154, wherein at least  $10^{10}$  cells are infused into the subject.

156. (previously presented): The method of claim 154, wherein the cells that are reinfused are greater than 50% Th1 cells.

157. (currently amended): The method of claim 154, wherein the monoclonal antibodies are specific for CD3 or CD2, combined with any combination of monoclonal antibodies specific for one or more of the following: CD4, CD8, CD5, CD11a, CD27, and CD28, ~~CD44 and CD45RO~~.

158. (previously presented): The method of claim 157, wherein the monoclonal antibodies are specific for CD3, CD5, and CD28.

159. (previously presented): The method of claim 154, wherein the cells are expanded in a hollow fiber bioreactor or a culture bag.

160. (canceled)

161. (new): The method of claim 154, wherein the monoclonal antibodies are specific for CD3 or CD2, combined with any combination of monoclonal antibodies specific for CD44 or CD45RO.